Palmitic Acid and Human Microvascular Function

Part of paid clinical trials in Wauwatosa, Wisconsin.

Sponsor
Medical College of Wisconsin
Study ID
NCT06683534
Phase
PHASE2
Status
Not Yet Recruiting

Notify me when recruiting opens

Save your spot on the interest list for this study. We'll keep your details with this study so our team can follow up when recruiting opens.

Not yet recruiting

Add your contact details and location so we can keep your interest tied to this study.

Conditions

  • Cardiovascular Diseases
  • Cardiovascular Diseases (CVD)
  • Microvascular Dysfunction
  • Microvascular Health
  • Microvasculature
  • Obesity and Overweight

Eligibility Criteria

Sex
ALL
Age
18 Years - 40 Years
Healthy Volunteers
Not accepted

Interventions

  • Quercetin (dietary supplement) — DIETARY_SUPPLEMENT
    Quercetin will be provided to take one Quercetin per day for 30 days to look for differences in microvascular function.
  • Placebo — DRUG
    Subjects randomized to receive placebo will be administered a standard placebo sugar pill.

Study Details

The goal of this study is to learn how a supplement Quercetin can affect microvascular function. Participants will: * give two blood draws of 5 mL each * have a camera placed under the tongue to take pictures of blood vessels * have 2 laser Doppler microdialysis catheters placed on the forearm to monitor blood vessels before and after local drug infusion Researchers will compare blood vessel function of those who take estrogen supplements to those who do not.

Key Dates

Start date
Jul 31, 2026
Status verified
Apr 2026
Primary completion
Dec 31, 2030
Completion
Dec 31, 2030

Study Design

Enrollment
40 participants (estimated)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
BASIC_SCIENCE

Arms

  • Experimental: Use of oral quercetin to improve human microvascular function
    Quercetin is a non-FDA approved, over-the-counter supplement that has been shown to improve oxidative capacity in blood vessels.
  • Placebo Comparator: Placebo
    A placebo will be administered for 30 days followed by assessment of the subject's microvascular function.

Primary Outcome Measure

Change in blood vessel dilation [ Time Frame: 2 hours ]

Central Contacts

Locations (1)

FacilityCityStateZIPSite coordinators
Froedtert HospitalWauwatosaWisconsin53226
Julia Vogt
[email protected]
4149552348
Julie Freed, MD, PhD (PRINCIPAL_INVESTIGATOR)

Find similar trials in Wauwatosa, WI

By research site
Froedtert Hospital· Wauwatosa, WI

Related Studies